

DECEMBER 31, 2019

INOVIO coronavirus experts learn about a novel coronavirus (SARS-CoV-2) which caused an outbreak of respiratory disease in Wuhan, China, now referred to as **COVID-19**

JANUARY 10, 2020

Chinese researchers share the genetic sequence of the novel coronavirus

INOVIO designs **DNA vaccine INO-4800 in three hours** after receiving the genetic sequence using its proprietary **DNA medicines platform technology**

INO-4800 was designed to precisely match the DNA sequence of the virus

JANUARY 10 - JANUARY 23, 2020

INOVIO coronavirus experts race to **manufacture INO-4800 and begin preclinical testing**

JANUARY 23, 2020

INOVIO receives a grant of up to **\$9 million from the Coalition for Epidemic Preparedness Innovations (CEPI)** to fund ongoing preclinical and initial clinical development of INO-4800

CEPI

JANUARY 23 - FEBRUARY 29, 2020

Preclinical testing continues, with immune responses generated in animal models; initial preclinical data submitted to peer-reviewed journal; human clinical trial designs developed and shared with regulators

MARCH 2020

Ongoing preclinical studies, including challenge studies; initial preclinical data **“under consideration”** at peer-reviewed journal; **human clinical trial designs finalized; 3,000 human trial doses prepared for clinical trials in the U.S., China, and South Korea**; large-scale manufacturing plans developed

MARCH 12, 2020

INOVIO announces **\$5 million grant from the Bill & Melinda Gates Foundation** to continue advancing the development of INO-4800, specifically to accelerate the testing and scale up of INOVIO’s proprietary smart device CELLECTRA® 3PSP

MARCH 26, 2020

INOVIO announces the **Department of Defense (DOD)** awarded Ology Bioservices an **\$11.9 million** contract to work with INOVIO on DNA technology transfer to rapidly manufacture INO-4800 for the DOD for upcoming clinical trials



APRIL 6, 2020

INOVIO announces initiation of Phase 1 human clinical trial in the U.S. following authorization by the U.S. Food and Drug Administration of its Investigative New Drug (IND) application

U.S. study to include up to 40 healthy volunteers; study sites are the University of Pennsylvania and a clinic in Kansas City, MO

Preclinical studies, including challenge studies, continue

SPRING - SUMMER 2020

U.S. Phase 1 study initial immune responses and safety data expected by late summer

Human clinical trials expected to begin in China and South Korea;** CEPI provides \$6.9 million to INOVIO, International Vaccine Institute and Korea National Institute of Health for Phase 1/2 study


FALL 2020

Upon successful completion of Phase 1 study, Phase 2 trial to begin

Human clinical trial results presented/published

END OF 2020

1 million doses of INO-4800 COVID-19 DNA vaccine planned for production**



*No toxicology testing required per FDA latest guidance; timelines are subject to change pending study results and regulatory guidance

** Pending appropriate regulatory guidance and external funding